The PhRMA Medicines in Development reports are almost hard to read because it’s hard to wrap your head around some of the numbers. The latest from the group looks at
Look, you’ve all seen the news, so I probably don’t need to provide the details: Lilly won FDA approval for Zepbound in obesity. It’s the same ingredient in Mounjaro and
The Wall Street Journal covered, with some depth, the trend of biosimilars launching with two prices: a low price designed to be appealing to consumers (and, I guess, media) and
Look, the evidence is clear: hospitals are taking in a ton of 340B money, and we don’t know where it goes. But the circumstantial evidence is that it doesn’t go
Medicare Benes Pay 33 Cents a Day for Insulin, HHS Says, Showing Why Access Is as Important as Price
It’s moving week at the Cost Curve offices, so the newsletter -- while it will appear -- is going to show up at slightly more random times. Thanks for your
My default assumption about most of the PBM reform proposals that have been circulating on Capitol Hill is that they’re smallball: they snack around the edge of the PBM business
Lots of earnings this morning that I haven’t processed yet. Hoping to give those a good look this weekend. Until then … The government formally responded to AstraZeneca’s lawsuit alleging
So I managed to screw up at least two things yesterday. First off, I misspelled Leana Wen’s name. Second, I included the wrong link in discussing Wen’s op-ed. The right
Yesterday was all about Eliquis. First up were the patient listening sessions I keep prattling on about. And while there was some sense that the parade of speakers didn’t shed
Below are transcripts (PDF) for all of the speakers at the CMS patient-focused listening sessions. Where possible, we've provided affiliations. CMS refers to speakers only with their first name, so
